sc13g


	OMB APPROVAL
	OMB Number: 3235-0145
	Expires: February 28, 2009
	Estimated average burden hours per response...11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. )*

Hana Biosciences, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

268749108

(CUSIP Number)

April 13, 2006**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

þ Rule 13d-1(c)

o Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

** The date set forth above is the date that the shares owned by the undersighned, his spouse and children, as well as their respective trusts, exceeded 5% of the oustanding shares of common stock.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.


CUSIP No.		268749108		Page		2		of		6


1	NAMES OF REPORTING PERSONS: Larry Gellman

	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):


2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
	(a) o
	(b) o

3	SEC USE ONLY:



4	CITIZENSHIP OR PLACE OF ORGANIZATION:

	United States of America

		5	SOLE VOTING POWER:

NUMBER OF			676,600 (See Item 4)

SHARES		6	SHARED VOTING POWER:
BENEFICIALLY
OWNED BY			1,137,500

EACH		7	SOLE DISPOSITIVE POWER:
REPORTING
PERSON			676,600

WITH:		8	SHARED DISPOSITIVE POWER:

			1,137,500

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

	1,814,100

10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

	o

11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

	8.1%

12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

	IN

- 2 -

SCHEDULE 13G
LARRY GELLMAN
HANA BIOSCIENCES, INC.


Item 1.

	(a)	Name of Issuer:

		Hana Biosciences, Inc.

	(b)	Address of Issuer’s Principal Executive Offices:

		400 Oyster Point Boulevard, Suite 215 South San Francisco, CA 94080

Item 2.

	(a)	Name of Person Filing:

		Larry Gellman

	(b)	Address of Principal Business Office or, if none, Residence:

		Larry Gellman 4405 N. Black Rock Drive Tucson, AZ 85750

	(c)	Citizenship:

		United States of America

	(d)	Title of Class of Securities:

		Common Stock, $0.001 par value

	(e)	CUSIP No.:

		268749108

- 3 -


Item 3.		If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

	(a)	o	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

	(b)	o	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

	(c)	o	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

	(d)	o	Investment company registered under section 8 of the Investment Company Act (15 U.S.C. 80a-8).

	(e)	o	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

	(f)	o	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

	(g)	o	A parent holding company or control plan, in accordance with §240.13d-1(b)(1)(ii)(G). (Note: See Item 7).

	(h)	o	A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

	(i)	o	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)

	(j)	o	Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4.		Ownership.

	(a)	Amount Beneficially Owned:

		1,814,100 shares. The undersigned declares that the filing of this statement shall not be construed as an admission that he is, for the purposes of Section 13(d) or 13(g) of the Exchange Act, the beneficial owner of the securities covered by this statement.

- 4 -


	(b)	Percent of Class:

		8.1%. Based upon 22,527,734 shares of common stock outstanding at March 22, 2006, as reported by Hana Biosciences, Inc. in its proxy statement filed with the SEC on April 7, 2006.

	(c)	Number of shares as to which such person has:

			(i)	Sole power to vote or to direct the vote

					676,600 shares.

			(ii)	Shared power to vote or to direct the vote

					1,137,500 shares, of which (a) 566,500 shares are held in the name of, or in trusts for the benefit of, Mr. Gellman’s spouse and children; and (b) 571,000 shares are held in client accounts where Mr. Gellman holds discretionary authority over such accounts.

			(iii)	Sole power to dispose or to direct the disposition of

					676,600 shares.

			(iv)	Shared power to dispose or to direct the disposition of

					1,137,500 shares, of which (a) 566,500 shares are held in the name of, or in trusts for the benefit of, Mr. Gellman’s spouse and children; and (b) 571,000 shares are held in client accounts where Mr. Gellman holds discretionary authority over such accounts.

Item 5.		Ownership of Five Percent or Less of a Class.

		If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o

Item 6.		Ownership of More than Five Percent on Behalf of Another Person.

		As reported above, Mr. Gellman beneficially owns 571,000 shares in client accounts where he holds discretionary authority over such accounts. The respective clients have the right to receive dividends from, and proceeds from the sale of, securities in these accounts. Mr. Gellman declares that his discretionary authority over client accounts shall not be construed as an admission that he is the beneficial owner of shares in such client accounts.

Item 7.		Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

- 5 -



				Not applicable.

Item 8.				Identification and Classification of Members of the Group.

				Not applicable.

Item 9.				Notice of Dissolution of Group.

				Not applicable.

Item 10.				Certification.

				By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: May 1, 2006.



	/s/ Larry Gellman
	Larry Gellman

- 6 -